Delving into the Latest Updates on Beijing Rundekang Medical Tech. Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Hemic and Lymphatic Diseases

Respiratory Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Chemical drugs	1

主要目的：观察中国健康志愿者在空腹/餐后服用受试制剂雷马曲班片（规格：75mg；生产企业：瑞阳制药有限公司）和参比制剂雷马曲班片（规格：75mg；生产企业：日本拜耳药品株式会社）后的药代动力学特征，评价空腹/餐后两种制剂的生物等效性。次要目的：观察受试制剂雷马曲班片和参比制剂雷马曲班片在中国健康志愿者中的安全性

[Translation]

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Ramaquban tablets (specification: 75 mg; manufacturer: Ruiyang Pharmaceutical Co., Ltd.) and the reference preparation Ramaquban tablets (specification: 75 mg; manufacturer: Bayer Pharmaceuticals Co., Ltd., Japan) in healthy Chinese volunteers after taking them on an empty stomach/after meals, and to evaluate the bioequivalence of the two preparations on an empty stomach/after meals. Secondary objective: To observe the safety of the test preparation Ramaquban tablets and the reference preparation Ramaquban tablets in healthy Chinese volunteers

Start Date30 May 2020

Sponsor / Collaborator

Beijing Rundekang Medical Tech. Co., Ltd.

CTR20191473 / Recruiting

雷马曲班片在中国健康志愿者中进行的人体生物等效性预试验

[Translation] A pilot human bioequivalence study of Lematroban tablets in Chinese healthy volunteers

主要目的：观察中国健康志愿者在空腹/餐后服用受试制剂雷马曲班片（规格：50mg；生产企业：瑞阳制药有限公司）和参比制剂雷马曲班片（规格：50mg；生产企业：日本拜耳药品株式会社）后的药代动力学特征，评价空腹/餐后两种制剂的生物等效性。次要目的：观察受试制剂雷马曲班片和参比制剂雷马曲班片在中国健康志愿者中的安全性

[Translation]

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Ramaquban tablets (specification: 50 mg; manufacturer: Ruiyang Pharmaceutical Co., Ltd.) and the reference preparation Ramaquban tablets (specification: 50 mg; manufacturer: Bayer Pharmaceuticals Co., Ltd., Japan) in healthy Chinese volunteers after taking them on an empty stomach/after meals, and to evaluate the bioequivalence of the two preparations on an empty stomach/after meals. Secondary objective: To observe the safety of the test preparation Ramaquban tablets and the reference preparation Ramaquban tablets in healthy Chinese volunteers

Start Date22 May 2020

Sponsor / Collaborator

Beijing Rundekang Medical Tech. Co., Ltd.

CTR20190508 / Completed

盐酸氯卡色林片在中国健康受试者中进行的人体生物等效性预试验

[Translation] A pilot human bioequivalence study of lorcaserin hydrochloride tablets in healthy Chinese subjects

初步观察中国健康受试者在空腹状态下单次口服受试制剂盐酸氯卡色林片（规格：10mg；生产企业：瑞阳制药有限公司）和参比制剂盐酸氯卡色林片（商品名：BELVIQ®；规格：10mg；生产企业：EISAI INC）后的药代动力学特征，进行药代动力学关键参数的比较；为正式试验提供研究依据。

[Translation]

To preliminarily observe the pharmacokinetic characteristics of the test preparation lorcaserin hydrochloride tablets (specification: 10 mg; manufacturer: Ruiyang Pharmaceutical Co., Ltd.) and the reference preparation lorcaserin hydrochloride tablets (trade name: BELVIQ®; specification: 10 mg; manufacturer: EISAI INC) after a single oral administration in Chinese healthy subjects in the fasting state, and compare the key pharmacokinetic parameters; to provide research basis for formal trials.

Start Date06 Aug 2019

Sponsor / Collaborator

Beijing Rundekang Medical Tech. Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Rundekang Medical Tech. Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Rundekang Medical Tech. Co., Ltd.

Login to view more data

100 Deals associated with Beijing Rundekang Medical Tech. Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Rundekang Medical Tech. Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Phase 3 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AK001 (Beijing Rundekang)	Community Acquired Pneumonia More	Phase 3
Sodium Feredetate	Anemia, Iron-Deficiency More	Phase 2
Pirfenidone	Idiopathic Pulmonary Fibrosis More	Pending